Global Colorectal Cancer Therapeutics Market Size Insights Forecasts to 2033

• The Global Colorectal Cancer Therapeutics Market Size was Valued at USD 12.71 Billion in 2023
• The Market Size is Growing at a CAGR of 4.59% from 2023 to 2033
• The Worldwide Colorectal Cancer Therapeutics Market Size is Expected to Reach USD 19.90 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Colorectal Cancer Therapeutics Market Size is Anticipated to Exceed USD 19.90 Billion by 2033, Growing at a CAGR of 4.59% from 2023 to 2033.

Market Overview

A specific type of tumor that appears in the rectum or colon (large intestine) is called colorectal cancer. It is one of the most common kinds of cancer in the world. The second most deadly tumor type and the third most prevalent is colorectal cancer. According to the World Cancer Research Fund International, (WCRFI), based on the most recent colorectal cancer data, 1,926,425 new cases of colorectal cancer were diagnosed in 2022. The World Health Organization estimates that cancer claims the lives of about 10 million people annually and is one of the top causes of death worldwide. Mutations in cancer driver genes lead to uncontrollable cell growth, which is the disease's cause. It might result in fatalities or other severe injuries. As people age, their risk of colorectal cancer increases. Most of the cases involve people who are over fifty. Diarrhea, constipation, blood in the stool, stomach pain, unusual weight loss, fatigue, and iron shortage are typical symptoms. Reduced alcohol intake, stopping smoking, eating a balanced diet, and regular exercise can all help to reduce the risk of colorectal cancer. Screening regularly is essential for early detection. With around 10 million fatalities from the disease each year, cancer is one of the leading causes of mortality worldwide. To better diagnosis and therapy, scientists are utilizing precision oncology, artificial intelligence, DNA sequencing, and other technologies. In partnership with the World Economic Forum, the Centre for the Fourth Industrial Revolution India aims to expedite eighteen cancer interventions. The colorectal cancer market is a complex perspective of medications, diagnostics, and healthcare services targeted at preventing, diagnosing, and managing colorectal cancer. The integration of digital health tools and telemedicine represents a transformative possibility for the colorectal cancer treatment market. As technology transforms healthcare delivery, the combination of digital solutions and telemedicine provides a multidimensional approach to improving patient care and treatment outcomes in colorectal cancer.

Report Coverage

This research report categorizes the market for the colorectal cancer therapeutics market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the colorectal cancer therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the colorectal cancer therapeutics market.

Driving Factors

The colorectal cancer drugs market is fueled by rising awareness of colorectal cancer and a corresponding increase in product introductions. Effective colorectal cancer therapy through therapeutics requires a multifaceted strategy, which may result in the use of a combination therapy consisting of many drugs. Furthermore, the colorectal cancer therapeutics industry is driven by rapid regulatory approvals of innovative medications and cures. The regulatory authorization is an important endorsement of the safety and efficacy of breakthrough medicines, inspiring trust in healthcare professionals, patients, and investors. Growing awareness initiatives and screening programs have resulted in earlier detection and diagnosis of colorectal cancer. Early diagnosis allows for earlier intervention and treatment, which improves patient outcomes.

Restraining Factors

Treatment failure and disease progression may result from colorectal cancer cells gradual development of resistance to particular medicines. Improving patient outcomes and preserving long-term efficacy are difficult tasks when drug resistance develops which hampers the colorectal cancer drugs market.

Market Segmentation

The colorectal cancer therapeutics market share is classified into therapy, cancer type, and distribution channel.

• The targeted therapy segment holds the largest market share through the forecast period.

Based on the therapy, the colorectal cancer therapeutics market is categorized into targeted therapy, immunotherapy, chemotherapy, and others. Among these, the targeted therapy segment holds the largest market share through the forecast period. Targeted therapy is a novel method that has effectively increased overall survival in colorectal cancer therapeutics patients. This is specifically due to their status as effective and sophisticated treatments, along with the essential life-saving functions that targeted therapy provides.

• The colorectal adenocarcinoma segment is anticipated to grow at the highest CAGR during the forecast period.

Based on the cancer type, the colorectal cancer therapeutics market is categorized into colorectal adenocarcinoma, gastrointestinal carcinoid tumors, and others. Among these, the colorectal adenocarcinoma segment is anticipated to grow at the highest CAGR during the forecast period. This is mainly because colorectal adenocarcinoma accounts for a significant proportion of colorectal cancer cases worldwide. Other factors driving growth in the colorectal adenocarcinoma segment include its high market value in terms of treatment and the prevalence of a rarer variant of colorectal adenocarcinoma that necessitates aggressive therapy.

• The hospital pharmacies segment is expected to grow at a significant pace in the colorectal cancer therapeutics market during the forecast period.

Based on the distribution channel, the colorectal cancer therapeutics market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others. Among these, the hospital pharmacies segment is expected to grow at a significant pace in the colorectal cancer therapeutics market during the forecast period. Hospital pharmacies administer drugs to patients undergoing inpatient or outpatient care in hospital settings. This is because drugs are frequently administered with a comprehensive diagnosis, which is commonly performed at these institutes. Furthermore, the drugs can only be provided intravenously by trained medical experts at specific locations.

Regional Segment Analysis of the Colorectal Cancer Therapeutics Market 

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the colorectal cancer therapeutics market over the predicted timeframe.

North America is projected to hold the largest share of the colorectal cancer therapeutics market over the forecast period. North America represents the greatest proportion of the studied market, owing to the rising incidence of colorectal cancer in the United States, as well as several initiatives. According to the American Cancer Society, colorectal cancer is one of the most prevalent malignancies diagnosed in men and women in the United States, with an estimated 104,270 additional instances of colon cancer and 45,230 new cases of rectal cancer have been recorded. Further, it is expected to reach 152,810 in the United States by 2024. As a result, as the number of cases of colorectal cancer diagnoses rises each year, so does the need for efficient treatment strategies to address the illness. Reported in the United States in 2021 colorectal cancer (CRC) remains the top cause of cancer-related death in the United States, in addition to early cancer-related death in Canada. Some of the reasons driving the growth of the colorectal cancer therapies market in the US include key product launches, a high concentration of market players or manufacturing presence, and acquisitions and collaborations among significant companies.

Asia Pacific is expected to grow at the fastest CAGR growth in the colorectal cancer therapeutics market during the forecast period. There is a growing senior citizen population and increased participation of public and private institutions in colorectal cancer awareness campaigns. For example, according to a report published in the National Library of Medicine in April 2022, various trial population-based CRC screening programs have been introduced in some administrative divisions of China, which can aid in the early identification and treatment of these conditions. Colorectal cancer awareness is increasing as disposable incomes rise across the region. The rising frequency of colorectal cancer in the region's important countries, alongside the rising status of colorectal disorders as the leading cause of death, is expected to fuel regional colorectal cancer drug market expansion.

The market is expected to develop significantly in Europe due to the large number of people who are suffering from colorectal cancer. The United Kingdom, France, and Spain are among the high-growth nations that will aid in the expansion of the European market.

Due to the rising incidence and knowledge of colorectal cancer, it is expected that the Latin American market for this disease will rise steadily. In comparison with other regions, the Middle East and Africa are predicted to grow less in the current scenario but to expand more in the eventual future.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the colorectal cancer therapeutics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Bayer AG
• Bristol Myers Squibb
• Eli Lilly and Company
• Genentech, Inc.
• Ipsen Biopharmaceuticals, Inc.
• Merck Sharp & Dohme Corp.
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Taiho Pharmaceutical
• Novartis AG
• Amgen Inc.
• Johnson & Johnson
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In February 2024, Reese Pharmaceutical widened its diagnostic line through the launch of a new at-home colon cancer screening test. The over-the-counter test is FDA-approved and available currently. The test is a fecal immunochemical test that can identify blood in the feces even if it cannot be seen with the naked eye. This can be utilized as an early warning indication of colon cancer, and also for other disorders such as diverticulitis and polyps. The test's indicated retail price is $19.99.

• In October 2023, Amgen released results from the global Phase 3 CodeBreaK 300 trial, which compared two dosages of LUMAKRAS (sotorasib) (960 mg or 240 mg) in combination with Vectibix (panitumumab). Both doses indicated a statistically significant advantage in progression-free survival (PFS) compared to the investigator's choice of therapy in patients with chemo refractory KRAS G12C-mutated metastatic colorectal cancer (mCRC).

• In January 2023, HUTCHMED granted Takeda a license to develop and sell Fruquintinib outside China. This strategic strategy enabled the organization to increase its regional reach and revenue.

• In June 2021, The European Commission (EC) approved Opdivo plus Yervoy for the treatment of adult patients with metastatic colorectal cancer that has microsatellite instability (MSI-H) (mCRC). This news was released by Bristol Myers Squibb. It can be used in all EU member states as well as Norway, Iceland, and Liechtenstein due to marketing approval.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the colorectal cancer therapeutics market based on the below-mentioned segments: 

Global Colorectal Cancer Therapeutics Market, By Therapy

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Others

Global Colorectal Cancer Therapeutics Market, By Cancer Type

• Colorectal Adenocarcinoma
• Gastrointestinal Carcinoid Tumors
• Others

Global Colorectal Cancer Therapeutics Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Colorectal Cancer Therapeutics Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa